Methylene blue: Difference between revisions
ClaireLewis (talk | contribs) |
Elcatracho (talk | contribs) |
||
| Line 46: | Line 46: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Promotes non-enzymatic redox conversion of methemoglobin to hemoglobin | *Promotes non-enzymatic redox conversion of methemoglobin to hemoglobin | ||
*Improves vascular tone via inhibition of nitric oxide synthase | |||
==Comments== | ==Comments== | ||
Latest revision as of 23:19, 28 December 2023
Administration
- Type: Antidote, Vasopressors
- Routes of Administration: IV
Adult Dosing
- Acquired methemoglobinemia: 1 mg/kg IV over 5-30min, may repeat in 1h with up to 1 mg/kg IV if methemoglobin level still >30% or symptoms persist
- Drug-induced methemoglobinemia: 1-2 mg/kg IV slowly over several minutes
- See vasopressors
- For hypotension refractory to catecholamine pressors
- Consider after catecholamine, vasopressin, and mineralocorticoid refractive shock
Pediatric Dosing
- Same as weight-based adult dosing
Special Populations
- Pregnancy Rating: X, Fetal risk has been demonstrated
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: no adjustment
- Hepatic dosing: no adjustment
Contraindications
- Allergy to class/drug
- G6PD deficiency
- ARDS
- Pulmonary hypertension
Adverse Reactions
Serious[1]
- Hemolytic anemia
- Syncope
- Serotonin syndrome
- Paradoxical methemoglobinemia at doses > 4 mg/kg/hr or per bolus
- Pulmonary vasoconstriction at 3-4 mg/kg/hr or per bolus
Common
- Skin discoloration, urine discoloration, hyperhidrosis
- Nausea, abnormal taste
- Limb pain
- Dizziness, headache
Pharmacology
- Half-life: 24h
- Metabolism: Hepatic
- Excretion: Mostly renal
Mechanism of Action
- Promotes non-enzymatic redox conversion of methemoglobin to hemoglobin
- Improves vascular tone via inhibition of nitric oxide synthase
Comments
See Also
References
- ↑ Pasin L et al. Methylene blue as a vasopressor: a meta-analysis of randomised trials. Crit Care Resusc. 2013 Mar;15(1):42-8.
